The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.

Oncotarget · 2016 · PMC5094963 · PMID 26993607

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

showed a trendp = 0,11not close (p > 0.1)

The results showed a trend toward a benefit for patients in the third-line TKI group: mOS 26 vs 15 months (third-line TKI vs second-line TKI), HR: 0,68, 95% CI: 0,42–1,09; p = 0,11.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.